• Clifford R Jack, Josephine Barnes, Matt A Bernstein, Bret J Borowski, James Brewer, Shona Clegg, Anders M Dale, Owen Carmichael, Christopher Ching, Charles DeCarli, Rahul S Desikan, Christine Fennema-Notestine, Anders M Fjell, Evan Fletcher, Nick C Fox, Jeff Gunter, Boris A Gutman, Dominic Holland, Xue Hua, Philip Insel, Kejal Kantarci, Ron J Killiany, Gunnar Krueger, Kelvin K Leung, Scott Mackin, Pauline Maillard, Ian B Malone, Niklas Mattsson, Linda McEvoy, Marc Modat, Susanne Mueller, Rachel Nosheny, Sebastien Ourselin, Norbert Schuff, Matthew L Senjem, Alix Simonson, Paul M Thompson, Dan Rettmann, Prashanthi Vemuri, Kristine Walhovd, Yansong Zhao, Samantha Zuk, and Michael Weiner.
• Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: jack.clifford@mayo.edu.
• Alzheimers Dement. 2015 Jul 1; 11 (7): 740-56.

IntroductionAlzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.MethodsWe review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3.ResultsContributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.DiscussionOver the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…